Quinazoline Derivatives for EGFR Inhibition
Solution Overview
Problem
There is a continuous need for compounds that effectively inhibit epidermal growth factor receptors to treat hyperproliferative diseases like cancer, with requirements for potency, stability, selectivity, toxicity, and pharmacokinetics properties that are not adequately met by existing solutions.
Innovation Solution
Development of novel quinazoline derivatives that act as potent inhibitors of the ErbB family of protein tyrosine kinases, including EGFR, which are used in pharmaceutical compositions to treat hyperproliferative disorders, including cancer, by targeting the epidermal growth factor receptor signaling pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EGFR inhibitors are used, then cancer treatment is achieved, but potency, stability, selectivity, toxicity and pharmacokinetics properties are not adequately met
Solution Approach 1:
The patent modifies the chemical structure of quinazoline derivatives by changing parameters such as substituting different groups at the R1 position (hydrogen, deuterium, fluorine, chlorine, bromine, or various alkyl/alkenyl/alkynyl groups) and modifying the Ar substituent on the aniline nitrogen. These parameter changes in molecular structure are designed to optimize multiple properties simultaneously including potency, stability, selectivity, toxicity profile, and pharmacokinetics, thereby resolving the contradiction between achieving reliable therapeutic efficacy and maintaining adequate adaptability across multiple pharmacological parameters.
2Reliability
If novel quinazoline derivatives are developed, then multiple properties (potency, stability, selectivity, toxicity, pharmacokinetics) can be optimized, but development complexity increases
Solution Approach 1:
The patent segments the quinazoline derivative molecule into distinct functional regions: the core quinazoline ring system, the R1 substituent at position 7, the aniline nitrogen at position 4, and the Ar aromatic substituent. This segmentation allows independent optimization of each region's properties - the core provides the EGFR binding scaffold, R1 modulates metabolic stability and pharmacokinetics, and Ar influences potency and selectivity. By dividing the molecular design into manageable segments, the patent achieves multi-parameter optimization without overwhelming complexity.
Data Source
Figure 1~2
AI summary
Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof,and method of use thereof.